| 1 |
32682148 | B cell modulation strategies in the improvement of transplantation outcomes. | 2020 Sep |
1 |
| 2 |
30834235 | Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53. | 2019 |
1 |
| 3 |
30442119 | Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. | 2018 Nov 15 |
2 |
| 4 |
30466749 | Should immunologic strategies be incorporated into frontline ALL therapy? | 2018 Dec |
1 |
| 5 |
28152223 | Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. | 2017 May |
1 |
| 6 |
27154915 | Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma. | 2016 Oct 1 |
2 |
| 7 |
25775418 | Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas. | 2015 Apr |
1 |
| 8 |
23313065 | Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin. | 2013 Jun |
1 |
| 9 |
21869836 | The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. | 2012 Feb |
1 |
| 10 |
22335424 | Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. | 2012 May |
2 |
| 11 |
22500551 | Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. | 2012 Jun |
1 |
| 12 |
20521053 | Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP. | 2011 Apr |
3 |
| 13 |
20308665 | Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. | 2010 Apr 20 |
1 |
| 14 |
20491780 | Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. | 2010 Aug |
2 |
| 15 |
20528256 | Inotuzumab ozogamicin as novel therapy in lymphomas. | 2010 Aug |
1 |
| 16 |
19369961 | CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. | 2009 Jul |
2 |
| 17 |
19388933 | CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. | 2009 Jun |
2 |